Evidence map›Paper›PMID 38229241›Full record

ArticleESC heart failure2024

Medicines optimization prior to discharge in patients admitted to hospital with heart failure.

Joseph J Cuthbert, Oliver I Brown, Pierpaolo Pellicori, Karen Dobbs, Jeanne Bulemfu, Syed Kazmi, Ioanna Sokoreli, Steffan C Pauws, Jarno M Riistama, John G F Cleland and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESC heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Joseph J CuthbertClinical Sciences Centre, Hull York Medical School, University of Hull, Kingston upon Hull, East Riding of Yorkshire, UK.ORCID https://orcid.org/0000-0003-4339-3062
Oliver I BrownClinical Sciences Centre, Hull York Medical School, University of Hull, Kingston upon Hull, East Riding of Yorkshire, UK.
Pierpaolo PellicoriBritish Heart Foundation Centre of Research Excellence, School of Cardiovascular and Metabolic Health, University of Glasgow, 126 University Place, Glasgow, Glasgow, G12 8TA, Lanarkshire, UK.
Karen DobbsClinical Sciences Centre, Hull York Medical School, University of Hull, Kingston upon Hull, East Riding of Yorkshire, UK.
Jeanne BulemfuClinical Sciences Centre, Hull York Medical School, University of Hull, Kingston upon Hull, East Riding of Yorkshire, UK.
Syed KazmiClinical Sciences Centre, Hull York Medical School, University of Hull, Kingston upon Hull, East Riding of Yorkshire, UK.
Ioanna SokoreliRemote Patient Management and Chronic Care, Philips Research Eindhoven, Eindhoven, The Netherlands.
Steffan C PauwsRemote Patient Management and Chronic Care, Philips Research Eindhoven, Eindhoven, The Netherlands.
Jarno M RiistamaPhilips Image Guided Therapy Devices, Best, The Netherlands.
John G F ClelandBritish Heart Foundation Centre of Research Excellence, School of Cardiovascular and Metabolic Health, University of Glasgow, 126 University Place, Glasgow, Glasgow, G12 8TA, Lanarkshire, UK.
Andrew L ClarkDepartment of Cardiology, Hull University Teaching Hospital Trust, Castle Hill Hospital, Kingston upon Hull, East Riding of Yorkshire, UK.
University of Hull · GBBritish Heart Foundation · GBNXP (Netherlands) · NLHull and East Yorkshire Hospitals NHS Trust · GBPhilips (Finland) · FI

Funding

British Heart Foundation Centre of Research Excellence RE/18/6/34217
6 · The paper itself

Abstract

aimsApproximately half of patients with heart failure and a reduced ejection fraction (HeFREF) are discharged from hospital on triple therapy [angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs), beta-blockers (BBs), and mineralocorticoid receptor antagonists (MRAs)]. We investigated what proportion of patients are on optimal doses prior to discharge and how many might be eligible for initiation of sacubitril-valsartan or sodium-glucose co-transporter-2 inhibitors (SGLT2Is). METHODS AND

resultsBetween 2012 and 2017, 1277 patients admitted with suspected heart failure were enrolled at a single hospital serving a local community around Kingston upon Hull, UK. Eligibility for sacubitril-valsartan or SGLT2I was based on entry criteria for the PIONEER-HF, DAPA-HF, and EMPEROR-Reduced trials. Four hundred fifty-five patients had HeFREF with complete data on renal function, heart rate, and systolic blood pressure (SBP) prior to discharge. Eighty-three per cent of patients were taking an ACE-I or ARB, 85% a BB, and 63% an MRA at discharge. More than 60% of patients were eligible for sacubitril-valsartan and >70% for SGLT2I. Among those not already receiving a prescription, 37%, 28%, and 49% were eligible to start ACE-I or ARB, BB, and MRA, respectively. Low SBP (≤105 mmHg) was the most frequent explanation for failure to initiate or up-titrate therapy.

conclusionsMost patients admitted for heart failure are eligible for initiation of life-prolonging medications prior to discharge. A hospital admission may be a common missed opportunity to improve treatment for patients with HeFREF.

Indexed as

Heart FailurePatient DischargeAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsHospitalsHumansStroke VolumeTetrazolesTreatment OutcomeAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsTetrazolesDischargeHeart failureInpatientMedicine optimizationQuadruple therapy

Identifiers

PMID38229241
PMCPMC10966249
OpenAlexW4390952704

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.